PURPOSE: Tumoural @entity715 ( @entity715 ) is a major prognostic @entity157 ( @entity157 ). The efficacy of @entity2857 , the only treatment approved at an advanced stage, is limited. Based on previous data, selective internal radiation therapy (SIRT), or (90)Y radioembolization, seems an interesting option. We aimed to compare both treatments in this population. METHODS: We retrospectively compared @entity1 treated in two centres for @entity157 with @entity5 @entity715 . We compared @entity1349 ( @entity1349 ) between @entity1 treated with SIRT and @entity1 treated with @entity2857 . Analyses were performed before and after 1:1 matching with a propensity score for controlling indication bias, using a Cox proportional hazards model. RESULTS: A total of 151 @entity1 were analysed, 34 @entity1 treated with SIRT and 117 @entity1 treated with @entity2857 only. In the whole population, SIRT was associated with a higher median @entity1349 as compared with @entity2857 : 18.8 vs 6.5  months (log-rank p   <   0.001). There was an imbalance of baseline characteristics between @entity1 treated by SIRT and @entity2857 , which justified @entity1 matching with use of a propensity score: 24 @entity1 treated with SIRT could be matched with 24 @entity1 treated with @entity2857 . @entity1349 was estimated with a median of 26.2 vs 8.7  months in @entity1 treated with SIRT vs @entity2857 , respectively (log-rank p   =   0.054). Before and after @entity1 matching, the adjusted hazard ratio related to treatment by SIRT was estimated at 0.62 [95  % confidence interval (CI) 0.39-0.97] (p   =   0.037) and 0.40 (95  % CI 0.19-0.82) (p   =   0.013), respectively. CONCLUSION: SIRT seems more effective than @entity2857 in @entity1 presenting with @entity157 and @entity5 @entity715 . This hypothesis is being tested in prospective randomized trials.

Selective internal radiation therapy compared with @entity2857 for @entity157 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumoural'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'factor in hepatocellular carcinoma'] @entity715 :: ('MESH:D013927', 'Disease') :: ['portal vein thrombosis', 'PVT'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity715 :: (MESH:D013927,Disease) :: ['portal vein thrombosis']
